| Year |
Citation |
Score |
| 2020 |
Orrù M, Strathman HJ, Floris G, Scheggi S, Levant B, Bortolato M. The adverse effects of pramipexole on probability discounting are not reversed by acute D or D receptor antagonism. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 31983530 DOI: 10.1016/J.Euroneuro.2020.01.005 |
0.525 |
|
| 2018 |
Kaplan SV, Limbocker RA, Levant B, Johnson MA. Regional differences in dopamine release in the R6/2 mouse caudate putamen. Electroanalysis. 30: 1066-1072. PMID 29955208 DOI: 10.1002/Elan.201700827 |
0.342 |
|
| 2018 |
Levant B, Healy-Stoffel M. N-3 (Omega-3) Fatty Acids: Effects on Brain Dopamine Systems and Potential Role in the Etiology and Treatment of Neuropsychiatric Disorders. Cns & Neurological Disorders Drug Targets. PMID 29651972 DOI: 10.2174/1871527317666180412153612 |
0.762 |
|
| 2016 |
Pes R, Godar SC, Fox AT, Burgeno LM, Strathman HJ, Jarmolowicz DP, Devoto P, Levant B, Phillips PE, Fowler SC, Bortolato M. Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release. Neuropharmacology. PMID 27889491 DOI: 10.1016/J.Neuropharm.2016.11.014 |
0.474 |
|
| 2014 |
Chen J, Jiang C, Levant B, Li X, Zhao T, Wen B, Luo R, Sun D, Wang S. Pramipexole derivatives as potent and selective dopamine D(3) receptor agonists with improved human microsomal stability. Chemmedchem. 9: 2653-60. PMID 25338762 DOI: 10.1002/Cmdc.201402398 |
0.517 |
|
| 2014 |
Healy-Stoffel M, Omar Ahmad S, Stanford JA, Levant B. Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat. Brain Research. 1574: 113-9. PMID 24924804 DOI: 10.1016/J.Brainres.2014.05.045 |
0.772 |
|
| 2014 |
Chen J, Levant B, Jiang C, Keck TM, Newman AH, Wang S. Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D₃ receptor antagonists. Journal of Medicinal Chemistry. 57: 4962-8. PMID 24848155 DOI: 10.1021/Jm401798R |
0.516 |
|
| 2014 |
Russell KL, Berman NE, Gregg PR, Levant B. Fish oil improves motor function, limits blood-brain barrier disruption, and reduces Mmp9 gene expression in a rat model of juvenile traumatic brain injury. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 90: 5-11. PMID 24342130 DOI: 10.1016/J.Plefa.2013.11.003 |
0.564 |
|
| 2013 |
Russell KL, Berman NE, Levant B. Low brain DHA content worsens sensorimotor outcomes after TBI and decreases TBI-induced Timp1 expression in juvenile rats. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 89: 97-105. PMID 23796971 DOI: 10.1016/J.Plefa.2013.05.004 |
0.599 |
|
| 2013 |
Healy-Stoffel M, Ahmad SO, Stanford JA, Levant B. Altered nucleolar morphology in substantia nigra dopamine neurons following 6-hydroxydopamine lesion in rats. Neuroscience Letters. 546: 26-30. PMID 23643997 DOI: 10.1016/J.Neulet.2013.04.033 |
0.776 |
|
| 2012 |
Chen J, Levant B, Wang S. High-affinity and selective dopamine D₃ receptor full agonists. Bioorganic & Medicinal Chemistry Letters. 22: 5612-7. PMID 22871578 DOI: 10.1016/J.Bmcl.2012.07.003 |
0.482 |
|
| 2012 |
Healy-Stoffel M, Ahmad SO, Stanford JA, Levant B. A novel use of combined tyrosine hydroxylase and silver nucleolar staining to determine the effects of a unilateral intrastriatal 6-hydroxydopamine lesion in the substantia nigra: a stereological study. Journal of Neuroscience Methods. 210: 187-94. PMID 22850559 DOI: 10.1016/J.Jneumeth.2012.07.013 |
0.787 |
|
| 2011 |
Chen J, Collins GT, Levant B, Woods J, Deschamps JR, Wang S. CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist. Acs Medicinal Chemistry Letters. 2: 620-625. PMID 22125662 DOI: 10.1021/Ml200100T |
0.544 |
|
| 2011 |
Russell KL, Kutchko KM, Fowler SC, Berman NE, Levant B. Sensorimotor behavioral tests for use in a juvenile rat model of traumatic brain injury: assessment of sex differences. Journal of Neuroscience Methods. 199: 214-22. PMID 21600923 DOI: 10.1016/J.Jneumeth.2011.05.008 |
0.57 |
|
| 2011 |
Collins GT, Truong YN, Levant B, Chen J, Wang S, Woods JH. Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity. Psychopharmacology. 215: 609-20. PMID 21207013 DOI: 10.1007/S00213-010-2154-7 |
0.454 |
|
| 2011 |
Levant B, Zarcone TJ, Davis PF, Ozias MK, Fowler SC. Differences in methylphenidate dose response between periadolescent and adult rats in the familiar arena-novel alcove task. The Journal of Pharmacology and Experimental Therapeutics. 337: 83-91. PMID 21205916 DOI: 10.1124/jpet.110.174425 |
0.357 |
|
| 2010 |
Davis PF, Ozias MK, Carlson SE, Reed GA, Winter MK, McCarson KE, Levant B. Dopamine receptor alterations in female rats with diet-induced decreased brain docosahexaenoic acid (DHA): interactions with reproductive status. Nutritional Neuroscience. 13: 161-9. PMID 20670471 DOI: 10.1179/147683010X12611460764282 |
0.429 |
|
| 2010 |
Oien DB, Ortiz AN, Rittel AG, Dobrowsky RT, Johnson MA, Levant B, Fowler SC, Moskovitz J. Dopamine D(2) receptor function is compromised in the brain of the methionine sulfoxide reductase A knockout mouse. Journal of Neurochemistry. 114: 51-61. PMID 20374422 DOI: 10.1111/J.1471-4159.2010.06721.X |
0.533 |
|
| 2008 |
Chen J, Collins GT, Zhang J, Yang CY, Levant B, Woods J, Wang S. Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile. Journal of Medicinal Chemistry. 51: 5905-8. PMID 18785726 DOI: 10.1021/Jm800471H |
0.487 |
|
| 2008 |
Levant B, Ozias MK, Davis PF, Winter M, Russell KL, Carlson SE, Reed GA, McCarson KE. Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: Interactions with reproductive status in female rats. Psychoneuroendocrinology. 33: 1279-92. PMID 18707812 DOI: 10.1016/J.Psyneuen.2008.06.012 |
0.605 |
|
| 2008 |
Culver KE, Szechtman H, Levant B. Altered dopamine D2-like receptor binding in rats with behavioral sensitization to quinpirole: effects of pre-treatment with Ro 41-1049. European Journal of Pharmacology. 592: 67-72. PMID 18644362 DOI: 10.1016/J.Ejphar.2008.06.101 |
0.583 |
|
| 2008 |
Witkin JM, Levant B, Zapata A, Kaminski R, Gasior M. The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors. The Journal of Pharmacology and Experimental Therapeutics. 326: 930-8. PMID 18566292 DOI: 10.1124/jpet.108.139212 |
0.438 |
|
| 2008 |
Ahmad SO, Park JH, Radel JD, Levant B. Reduced numbers of dopamine neurons in the substantia nigra pars compacta and ventral tegmental area of rats fed an n-3 polyunsaturated fatty acid-deficient diet: a stereological study. Neuroscience Letters. 438: 303-7. PMID 18499349 DOI: 10.1016/J.Neulet.2008.04.073 |
0.407 |
|
| 2007 |
Richards TL, Pazdernik TL, Levant B. Basal local cerebral glucose utilization is not altered after behavioral sensitization to quinpirole. Neuroscience Letters. 429: 165-8. PMID 17997222 DOI: 10.1016/J.Neulet.2007.10.006 |
0.434 |
|
| 2007 |
Richards TL, Pazdernik TL, Levant B. Clorgyline-induced modification of behavioral sensitization to quinpirole: effects on local cerebral glucose utilization. Brain Research. 1160: 124-33. PMID 17573047 DOI: 10.1016/J.Brainres.2007.05.035 |
0.437 |
|
| 2007 |
Pierce JD, Jegathesan J, Levant B, Winter M, McCarson KE, Clancy RL. Detection of dopamine receptor subtypes in the rat diaphragm. Heart & Lung : the Journal of Critical Care. 36: 58-63. PMID 17234478 DOI: 10.1016/j.hrtlng.2006.05.009 |
0.531 |
|
| 2007 |
Levant B, Ozias MK, Carlson SE. Specific brain regions of female rats are differentially depleted of docosahexaenoic acid by reproductive activity and an (n-3) fatty acid-deficient diet. The Journal of Nutrition. 137: 130-4. PMID 17182813 DOI: 10.1093/Jn/137.1.130 |
0.348 |
|
| 2007 |
Ozias MK, Carlson SE, Levant B. Maternal parity and diet (n-3) polyunsaturated fatty acid concentration influence accretion of brain phospholipid docosahexaenoic acid in developing rats. The Journal of Nutrition. 137: 125-9. PMID 17182812 DOI: 10.1093/Jn/137.1.125 |
0.308 |
|
| 2007 |
Levant B. Characterization of Dopamine Receptors Current Protocols in Pharmacology. 36. DOI: 10.1002/0471141755.ph0106s36 |
0.493 |
|
| 2006 |
McNamara RK, Levant B, Taylor B, Ahlbrand R, Liu Y, Sullivan JR, Stanford K, Richtand NM. C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice. Neuroscience. 143: 141-53. PMID 16938406 DOI: 10.1016/J.Neuroscience.2006.07.015 |
0.383 |
|
| 2006 |
Levant B, Ozias MK, Jones KA, Carlson SE. Differential effects of modulation of docosahexaenoic acid content during development in specific regions of rat brain. Lipids. 41: 407-14. PMID 16933785 DOI: 10.1007/S11745-006-5114-6 |
0.355 |
|
| 2006 |
Levant B, Ozias MK, Carlson SE. Sex-specific effects of brain LC-PUFA composition on locomotor activity in rats. Physiology & Behavior. 89: 196-204. PMID 16875705 DOI: 10.1016/J.Physbeh.2006.06.007 |
0.355 |
|
| 2006 |
Levant B, Crane JF, Carlson SE. Sub-chronic antipsychotic drug treatment does not alter brain phospholipid fatty acid composition in rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 30: 728-32. PMID 16442197 DOI: 10.1016/J.Pnpbp.2005.11.034 |
0.327 |
|
| 2006 |
Chen J, Ding K, Levant B, Wang S. Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility. Bioorganic & Medicinal Chemistry Letters. 16: 443-6. PMID 16290142 DOI: 10.1016/J.Bmcl.2005.09.053 |
0.487 |
|
| 2006 |
Chen J, Ding K, Levant B, Wang S. Corrigendum to "Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility". [Bioorg. Med. Chem. Lett. 16 (2006) 443-446] (DOI:10.1016/j.bmcl.2005.09.053) Bioorganic and Medicinal Chemistry Letters. 16: 3868. DOI: 10.1016/J.Bmcl.2006.04.083 |
0.495 |
|
| 2005 |
Ding K, Chen J, Ji M, Wu X, Varady J, Yang CY, Lu Y, Deschamps JR, Levant B, Wang S. Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands. Journal of Medicinal Chemistry. 48: 3171-81. PMID 15857123 DOI: 10.1021/Jm049031L |
0.485 |
|
| 2005 |
Richards TL, Pazdernik TL, Levant B. Altered quinpirole-induced local cerebral glucose utilization in anterior cortical regions in rats after sensitization to quinpirole. Brain Research. 1042: 53-61. PMID 15823253 DOI: 10.1016/J.Brainres.2005.02.013 |
0.33 |
|
| 2005 |
Ji M, Chen J, Ding K, Wu X, Varady J, Levant B, Wang S. Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands. Bioorganic & Medicinal Chemistry Letters. 15: 1701-5. PMID 15745825 DOI: 10.1016/J.Bmcl.2005.01.037 |
0.478 |
|
| 2004 |
Ahlgren-Beckendorf JA, Levant B. Signaling mechanisms of the D3 dopamine receptor. Journal of Receptor and Signal Transduction Research. 24: 117-30. PMID 15521358 DOI: 10.1081/RRS-200029953 |
0.801 |
|
| 2004 |
Wu X, Chen J, Ji M, Varady J, Levant B, Wang S. Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands. Bioorganic & Medicinal Chemistry Letters. 14: 5813-6. PMID 15501046 DOI: 10.1016/J.Bmcl.2004.09.047 |
0.454 |
|
| 2004 |
Levant B, Radel JD, Carlson SE. Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation. Behavioural Brain Research. 152: 49-57. PMID 15135968 DOI: 10.1016/J.Bbr.2003.09.029 |
0.393 |
|
| 2004 |
Levant B, Pazdernik TL. Differential effects of ibogaine on local cerebral glucose utilization in drug-naive and morphine-dependent rats. Brain Research. 1003: 159-67. PMID 15019575 DOI: 10.1016/J.Brainres.2003.12.032 |
0.354 |
|
| 2004 |
Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Peters S, Shannon HE, Gasior M. Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]. The Journal of Pharmacology and Experimental Therapeutics. 308: 957-64. PMID 14711932 DOI: 10.1124/jpet.103.059980 |
0.493 |
|
| 2003 |
Varady J, Wu X, Fang X, Min J, Hu Z, Levant B, Wang S. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. Journal of Medicinal Chemistry. 46: 4377-92. PMID 14521403 DOI: 10.1021/Jm030085P |
0.434 |
|
| 2003 |
Richtand NM, Welge JA, Levant B, Logue AD, Hayes S, Pritchard LM, Geracioti TD, Coolen LM, Berger SP. Altered behavioral response to dopamine D3 receptor agonists 7-OH-DPAT and PD 128907 following repetitive amphetamine administration. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 1422-32. PMID 12700693 DOI: 10.1038/Sj.Npp.1300182 |
0.522 |
|
| 2003 |
Carpenter TL, Pazdernik TL, Levant B. Differences in quinpirole-induced local cerebral glucose utilization between naive and sensitized rats. Brain Research. 964: 295-301. PMID 12576190 DOI: 10.1016/S0006-8993(02)04115-X |
0.409 |
|
| 2003 |
Levant B. Dopamine receptor binding and quantitative autoradiographic study. Methods in Molecular Medicine. 79: 297-313. PMID 12506705 DOI: 10.1385/1-59259-358-5:297 |
0.524 |
|
| 2002 |
Levant B. Novel drug interactions at D(2) dopamine receptors: modulation of [3H]quinpirole binding by monoamine oxidase inhibitors. Life Sciences. 71: 2691-700. PMID 12383877 DOI: 10.1016/S0024-3205(02)02109-4 |
0.547 |
|
| 2001 |
Levant B, Morgan KA, Ahlgren-Beckendorf JA, Grandy DK, Chen K, Shih JC, Seif I. Modulation of [3H]quinpirole binding at striatal D2 dopamine receptors by a monoamine oxidaseA-like site: evidence from radioligand binding studies and D2 receptor- and MAO(A)-deficient mice. Life Sciences. 70: 229-41. PMID 11787947 DOI: 10.1016/S0024-3205(01)01400-X |
0.809 |
|
| 2001 |
Levant B, McCarson KE. D(3) dopamine receptors in rat spinal cord: implications for sensory and motor function. Neuroscience Letters. 303: 9-12. PMID 11297811 DOI: 10.1016/S0304-3940(01)01692-5 |
0.47 |
|
| 2001 |
Levant B. UNIT 1.6 Characterization of Dopamine Receptors Current Protocols in Pharmacology. DOI: 10.1002/0471141755.Ph0106S00 |
0.558 |
|
| 2000 |
Gilliland SL, Alper RH, Levant B. Pharmacology of quinpirole-stimulated [35S]GTPgammaS binding: discrepancy with receptor binding profile. European Journal of Pharmacology. 392: 125-8. PMID 10762663 DOI: 10.1016/S0014-2999(00)00124-2 |
0.818 |
|
| 1999 |
Levant B, Garimelli B, Shafer RA, Merchant KM. Increased levels of proneurotensin/neuromedin N mRNA in rat striatum and nucleus accumbens induced by 7-OH-DPAT and nafadotride. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 21: 304-11. PMID 10432478 DOI: 10.1016/S0893-133X(99)00033-0 |
0.726 |
|
| 1999 |
Levant B, Ling ZD, Carvey PM. Dopamine D3 Receptors Cns Drugs. 12: 391-402. DOI: 10.2165/00023210-199912050-00006 |
0.525 |
|
| 1999 |
Levant B, Ling ZD, Carvey PM. Dopamine D3 receptors: Relevance for the drug treatment of Parkinson's disease Cns Drugs. 12: 391-402. DOI: 10.2165/00023210-199912050-00006 |
0.493 |
|
| 1999 |
Levant B. NEUROBIOLOGY OF THE D3 DOPAMINE RECEPTOR Behavioural Pharmacology. 10: S57. DOI: 10.1097/00008877-199908001-00144 |
0.45 |
|
| 1998 |
Levant B, Cross RS, Pazdernik TL. Alterations in local cerebral glucose utilization produced by D3 dopamine receptor-selective doses of 7-OH-DPAT and nafadotride. Brain Research. 812: 193-9. PMID 9813322 DOI: 10.1016/S0006-8993(98)00924-X |
0.513 |
|
| 1998 |
Levant B, Bancroft GN. Inhibition of [3H]quinpirole binding by a monoamine oxidase inhibitor in subcellular fractions of rat striatum. Life Sciences. 63: 1643-51. PMID 9806217 DOI: 10.1016/S0024-3205(98)00433-0 |
0.805 |
|
| 1998 |
Levant B. Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Research. 800: 269-74. PMID 9685676 DOI: 10.1016/S0006-8993(98)00529-0 |
0.537 |
|
| 1998 |
Flietstra RJ, Levant B. Comparison of D2 and D3 dopamine receptor affinity of dopaminergic compounds in rat brain. Life Sciences. 62: 1825-31. PMID 9600324 DOI: 10.1016/S0024-3205(98)00148-9 |
0.818 |
|
| 1998 |
Bancroft GN, Morgan KA, Flietstra RJ, Levant B. Binding of [3H]PD 128907, a putatively selective ligand for the D3 dopamine receptor, in rat brain: a receptor binding and quantitative autoradiographic study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 18: 305-16. PMID 9509498 DOI: 10.1016/S0893-133X(97)00162-0 |
0.784 |
|
| 1998 |
Shafer RA, Levant B. The D3 dopamine receptor in cellular and organismal function. Psychopharmacology. 135: 1-16. PMID 9489928 DOI: 10.1007/s002130050479 |
0.771 |
|
| 1997 |
Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacological Reviews. 49: 231-52. PMID 9311022 |
0.411 |
|
| 1997 |
Levant B, Vansell NR. In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 17: 67-71. PMID 9252981 DOI: 10.1016/S0893-133X(97)00024-9 |
0.516 |
|
| 1997 |
Levant B, Bancroft GN, Selkirk CM, Vansell N. In vivo occupancy of D2 dopamine receptors by D3 receptor-selective drugs Schizophrenia Research. 24: 79. DOI: 10.1016/S0920-9964(97)82214-1 |
0.798 |
|
| 1996 |
Levant B, Bancroft GN, Selkirk CM. In vivo occupancy of D2 dopamine receptors by 7-OH-DPAT. Synapse (New York, N.Y.). 24: 60-4. PMID 9046077 DOI: 10.1002/(Sici)1098-2396(199609)24:1<60::Aid-Syn7>3.0.Co;2-E |
0.789 |
|
| 1996 |
Levant B, Moehlenkamp JD, Morgan KA, Leonard NL, Cheng CC. Modulation of [3H]quinpirole binding in brain by monoamine oxidase inhibitors: evidence for a potential novel binding site. The Journal of Pharmacology and Experimental Therapeutics. 278: 145-53. PMID 8764345 |
0.438 |
|
| 1996 |
Levant B, Moehlenkamp J, Morgan K. A potential novel binding site for mao inhibitors in brain Biological Psychiatry. 39: 593. DOI: 10.1016/0006-3223(96)84263-6 |
0.342 |
|
| 1995 |
Levant B. Differential sensitivity of [3H]7-OH-DPAT-labeled binding sites in rat brain to inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Brain Research. 698: 146-54. PMID 8581473 DOI: 10.1016/0006-8993(95)00879-U |
0.526 |
|
| 1995 |
Levant B, Grigoriadis DE, De Souza EB. Relative affinities of dopaminergic drugs at dopamine D2 and D3 receptors. European Journal of Pharmacology. 278: 243-7. PMID 7589161 DOI: 10.1016/0014-2999(95)00160-M |
0.453 |
|
| 1993 |
Levant B, Grigoriadis DE, DeSouza EB. [3H]quinpirole binding to putative D2 and D3 dopamine receptors in rat brain and pituitary gland: a quantitative autoradiographic study. The Journal of Pharmacology and Experimental Therapeutics. 264: 991-1001. PMID 8437136 |
0.828 |
|
| 1993 |
Levant B, Grigoriadis DE, DeSouza EB. Monoamine oxidase inhibitors inhibit [3H]quinpirole binding in rat striatal membranes. European Journal of Pharmacology. 246: 171-8. PMID 8104153 DOI: 10.1016/0922-4106(93)90095-Q |
0.799 |
|
| 1993 |
Levant B, DeSouza EB. Differential pharmacological profile of striatal and cerebellar dopamine receptors labeled by [3H]quinpirole: identification of a discrete population of putative D3 receptors. Synapse (New York, N.Y.). 14: 90-5. PMID 8099762 DOI: 10.1002/syn.890140112 |
0.822 |
|
| 1993 |
Levant B, Grigoriadis D, De Souza E. D3 dopamine receptors, a potential antipsychotic drug target: Identification and characterization of a discrete population in cerebellum Schizophrenia Research. 9: 242. DOI: 10.1016/0920-9964(93)90542-Q |
0.367 |
|
| 1992 |
Levant B, Nemeroff CB. Further studies on the modulation of regional brain neurotensin concentrations by antipsychotic drugs: focus on haloperidol and BMY 14802. The Journal of Pharmacology and Experimental Therapeutics. 262: 348-55. PMID 1625208 |
0.429 |
|
| 1992 |
Levant B, Grigoriadis DE, DeSouza EB. Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain. The Journal of Pharmacology and Experimental Therapeutics. 262: 929-35. PMID 1356154 |
0.83 |
|
| 1992 |
Levant B, Merchant KM, Dorsa DM, Nemeroff CB. BMY 14802, a potential antipsychotic drug, increases expression of proneurotensin mRNA in the rat striatum. Brain Research. Molecular Brain Research. 12: 279-84. PMID 1349718 DOI: 10.1016/0169-328X(92)90130-4 |
0.431 |
|
| 1992 |
Myers B, Levant B, Bissette G, Nemeroff CB. Pharmacological specificity of the increase in neurotensin concentrations after antipsychotic drug treatment. Brain Research. 575: 325-8. PMID 1349254 DOI: 10.1016/0006-8993(92)90098-T |
0.416 |
|
| 1992 |
BISSETTE G, LEVANT B, NEMEROFF C. A POTENTIAL ROLE FOR NEUROTENSIN IN MEDIATING THE THERAPEUTIC EFFECTS OF ANTIPSYCHOTIC DRUGS Behavioural Pharmacology. 3: 17. DOI: 10.1097/00008877-199204001-00049 |
0.311 |
|
| 1991 |
Levant B, Bissette G, Davis MD, Heffner TG, Nemeroff CB. Effects of CI-943, a potential antipsychotic drug, and haloperidol on regional brain neurotensin concentrations. Synapse (New York, N.Y.). 9: 225-30. PMID 1685600 DOI: 10.1002/syn.890090309 |
0.466 |
|
| 1991 |
Levant B, Bissette G, Widerlöv E, Nemeroff CB. Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs. Regulatory Peptides. 32: 193-201. PMID 1674615 DOI: 10.1016/0167-0115(91)90046-J |
0.414 |
|
| 1991 |
Nemeroff CB, Kilts CD, Levant B, Bissette G, Campbell A, Baldessarini RJ. Effects of the isomers of N-n-propylnorapomorphine and haloperidol on regional concentrations of neurotensin in rat brain. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 4: 27-33. PMID 1672249 |
0.474 |
|
| 1990 |
Levant B, Nemeroff CB. Sigma receptor "antagonist" BMY 14802 increases neurotensin concentrations in the rat nucleus accumbens and caudate. The Journal of Pharmacology and Experimental Therapeutics. 254: 330-5. PMID 1973198 |
0.499 |
|
| 1989 |
Levant B, Bissette G, Nemeroff CB. Effects of anticholinergic drugs on regional brain neurotensin concentrations. European Journal of Pharmacology. 165: 327-30. PMID 2776835 DOI: 10.1016/0014-2999(89)90731-0 |
0.383 |
|
| 1988 |
Levant B, Bissette G, Parker YM, Nemeroff CB. Alterations in neurotensin- and bombesin-like immunoreactivity in MPTP-treated mice Annals of the New York Academy of Sciences. 537: 515-517. DOI: 10.1111/J.1749-6632.1988.TB42144.X |
0.446 |
|
| Show low-probability matches. |